The estimated Net Worth of Kristine Yaffe is at least $941 Tysiąc dollars as of 12 August 2024. Kristine Yaffe owns over 5,000 units of Alector stock worth over $393,389 and over the last 5 years he sold ALEC stock worth over $25,300. In addition, he makes $522,253 as Independent Director at Alector.
Kristine has made over 2 trades of the Alector stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of ALEC stock worth $25,300 on 12 August 2024.
The largest trade he's ever made was selling 5,000 units of Alector stock on 12 August 2024 worth over $25,300. On average, Kristine trades about 1,000 units every 152 days since 2020. As of 12 August 2024 he still owns at least 67,709 units of Alector stock.
You can see the complete history of Kristine Yaffe stock trades at the bottom of the page.
Dr. Kristine Yaffe serves as Independent Director of the Company. Dr. Yaffe is currently a professor of psychiatry, neurology, and epidemiology at the University of California, San Francisco (UCSF) and has served in that role since 2007. Dr. Yaffe has also served as the Roy and Marie Scola Endowed Chair since 2009 and Vice Chair in Psychiatry at UCSF since 2016. Dr. Yaffe has received numerous awards for her groundbreaking contributions to the field including the American Academy of Neurology Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases. Dr. Yaffe holds a B.S. in biology-psychology from Yale University and an M.D. from the University of Pennsylvania School of Medicine and has completed residencies in neurology and psychiatry at UCSF.
As the Independent Director of Alector, the total compensation of Kristine Yaffe at Alector is $522,253. There are 6 executives at Alector getting paid more, with Arnon Rosenthal having the highest compensation of $6,854,340.
Kristine Yaffe is 57, he's been the Independent Director of Alector since 2019. There are 6 older and 12 younger executives at Alector. The oldest executive at Alector, Inc. is Louis Lavigne, 72, who is the Lead Independent Director.
Kristine's mailing address filed with the SEC is C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at Alector have traded over $148,873,269 worth of Alector stock and bought 20,000 units worth $500,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Advisors Llc Orbi Med Capit... oraz Terrance Mcguire. On average, Alector executives and independent directors trade stock every 17 days with the average trade being worth of $438,922. The most recent stock trade was executed by Marc Grasso on 3 September 2024, trading 7,297 units of ALEC stock currently worth $35,609.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector executives and other stock owners filed with the SEC include: